Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference

Company Overview - Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways [3] - The company is developing fatty acid synthase (FASN) inhibitors, with its lead drug candidate, denifanstat, aimed at treating metabolic dysfunction associated with steatohepatitis (MASH) [3] - Denifanstat is an oral, once-daily pill that has received Breakthrough Therapy designation from the FDA for treating non-cirrhotic MASH with moderate to advanced liver fibrosis [3] Clinical Trials and Developments - The FASCINATE-2 Phase 2b clinical trial of denifanstat in MASH has been successfully completed with positive results [3] - Sagimet has initiated a Phase 1 first-in-human clinical trial for a second oral FASN inhibitor, TVB-3567, which is planned for acne treatment in the US [3] Upcoming Events - Management will participate in a fireside chat at the Canaccord Genuity 45 Annual Growth Conference on August 13, 2025, at 2 p.m. EDT in Boston, MA [1] - A webcast of the fireside chat will be available on Sagimet's website, with an archived replay accessible for 90 days post-event [2]